TAKCIK 1395064

TAKEDA PHARMACEUTICAL CO LTD

EDGAR filings

Customers

2 federal agencies

Suppliers

1 disclosed

Federal obligations

$2.9M

FY2024 · USAspending.gov

Latest period

Dec 31, 2025

10-K filed 2026-03-13

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Suppliers 1

Companies that disclose TAK as a major customer, as a share of their own revenue. 1 active, 0 lapsed.

Company	% of their revenue	Est. $ from TAK	Period	Trend	Status	Source
NKTR NEKTAR THERAPEUTICS	Named	—	FY 2025-12-31	—	Active	10-K 2026-03-13
Revenue from Baxalta (a subsidiary of Takeda Pharmaceutical Company Limited), AstraZeneca, and UCB represented 45%, 37%, and 14% of our revenue, respectively, for the year ended December 31, 2025. 10-K filed 2026-03-13 Period FY 2025-01-01 to 2025-12-31Accession 0001193125-26-104547

Federal contracts 2

Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $2.9M in the latest fiscal year shown per agency.

Agency	Obligated	Fiscal year	Awards	Trend	Largest award
Department of Veterans Affairs Department of Veterans Affairs	$1.9M	FY 2024	49	$1.4M → $1.9M	36C26024F0417
LANADELUMAB-FLYO 150MG/ML INJ, SYRINGE,2ML (TAKHZYRO) Award 36C26024F0417 on USAspending.gov ↗ Largest of 49 awards in FY2024: $221.3K obligated
Department of Justice Federal Prison System / Bureau of Prisons	$1.0M	FY 2024	10	$1.3M → $1.0M	15B50924F00000168
FMC FORT WORTH TAKEDA MEDICATION ORDER FOR MAY AGAINST FSS V797D-50492 Award 15B50924F00000168 on USAspending.gov ↗ Largest of 10 awards in FY2024: $137.4K obligated

Alerts are coming

Get an email when TAK's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.